Unknown

Dataset Information

0

Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate.


ABSTRACT: Background:In the initial absence of specific reversal agents for factor Xa inhibitors (FXa-Is), prothrombin complex concentrate (PCC) as a hemostatic agent has been recommended by guidelines. Since 2017, idarucizumab has been registered for dabigatran reversal. Still, data on the clinical outcome of direct oral anticoagulant (DOAC)-related emergencies (major bleeding or urgent interventions) is scarce. In addition, it is unknown to what extent PCC restores thrombin generation in FXa-I-related emergencies. Our aim was to describe management and clinical outcomes of DOAC-related emergencies and to assess the laboratory effect of PCC in patients with FXa-I emergencies. Methods:In this prospective cohort study in 5 Dutch hospitals, patients presenting with DOAC-related emergencies were eligible. The primary outcome was effective hemostasis according to the ISTH definition. Safety outcomes were 30-day mortality and thromboembolic rate. In patients treated with PCC, additional blood samples were taken to assess the effect on thrombin generation. Results:We included 101 patients with major bleeding (FXa-I, 76; dabigatran, 25) and 21 patients requiring an urgent intervention (FXa-I, 16; dabigatran, 5). Of patients with major bleeding, 67% were treated with PCC or idarucizumab. Effective hemostasis, 30-day mortality, and thromboembolism rate were 67%, 22%, and 1%, respectively. In a subset of bleeding patients on FXa-I managed with PCC, thrombin generation increased, with 96% immediately after PCC administration. In patients requiring an urgent intervention, effective hemostasis, 30-day mortality, and thromboembolic rate were 95%, 14%, and 5%. Conclusions:Effective hemostasis was achieved in the majority of patients presenting with DOAC-related emergencies;, thromboembolic complications were rare, and mortality was quite high.

SUBMITTER: Bavalia R 

PROVIDER: S-EPMC7292661 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate.

Bavalia Roisin R   Abdoellakhan Rahat R   Brinkman Herm Jan M HJM   Brekelmans Marjolein P A MPA   Hamulyák Eva N EN   Zuurveld Marleen M   Hutten Barbara A BA   Westerweel Peter E PE   Olie Renske H RH   Ten Cate Hugo H   Kruip Marieke M   Middeldorp Saskia S   Meijer Karina K   Coppens Michiel M  

Research and practice in thrombosis and haemostasis 20200423 4


<h4>Background</h4>In the initial absence of specific reversal agents for factor Xa inhibitors (FXa-Is), prothrombin complex concentrate (PCC) as a hemostatic agent has been recommended by guidelines. Since 2017, idarucizumab has been registered for dabigatran reversal. Still, data on the clinical outcome of direct oral anticoagulant (DOAC)-related emergencies (major bleeding or urgent interventions) is scarce. In addition, it is unknown to what extent PCC restores thrombin generation in FXa-I-r  ...[more]

Similar Datasets

| S-EPMC6341194 | biostudies-literature
| S-EPMC3875114 | biostudies-other
| S-EPMC5433145 | biostudies-literature
| S-EPMC6714747 | biostudies-literature
| S-EPMC5310120 | biostudies-literature
| S-EPMC6423941 | biostudies-literature
| S-EPMC5529093 | biostudies-other
| S-EPMC6206466 | biostudies-other
| S-EPMC3487550 | biostudies-literature
| S-EPMC6714910 | biostudies-literature